Literature DB >> 10551768

Urinary 6-sulfatoxymelatonin excretion and aging: new results and a critical review of the literature.

D J Kennaway1, K Lushington, D Dawson, L Lack, C van den Heuvel, N Rogers.   

Abstract

The apparent age-related decline in melatonin production has been thought to continue in a secular manner across the lifespan. While it is clear that melatonin levels in children and adolescents are elevated compared to older individuals, the question of whether there is a sudden or gradual change has not been adequately addressed. In this study, we report the excretion of the melatonin metabolite, 6-sulfatoxymelatonin in 253 subjects aged between 21 and 82 yr. The correlation with age was significant (r = -0.24; P < 0.05). When the data was analysed by ANOVA using 5-yr age spans, there was a significant effect of age, but post hoc analysis indicated that after 25 yr of age there was no significant decline in excretion of the metabolite. Thus, although the oldest subjects excreted 36% less melatonin metabolite than the youngest, the decrease occurred at a very early age. In the second part of the study, we re-evaluated the data from seven previous studies that measured plasma melatonin levels or metabolite excretion across a wide range of ages and 11 studies comparing young versus older subjects. Statistical analysis by ANOVA again suggested that the changes in melatonin occurring with age were essentially complete before 30 yr of age. The youngest subjects produced at the most twice the amount of melatonin as the oldest subjects. Finally, we evaluated the mean plasma melatonin levels in 144 groups of normal subjects reported in 137 separate publications with respect to age. Again, whereas there was a significant correlation with age, ANOVA showed that there was no difference between groups after 35 yr of age, and the oldest groups had levels that were only 43% of the youngest groups. We conclude that melatonin production is lower in older people, but that the change occurs very early in life, around 20-30 yr of age.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10551768     DOI: 10.1111/j.1600-079x.1999.tb00617.x

Source DB:  PubMed          Journal:  J Pineal Res        ISSN: 0742-3098            Impact factor:   13.007


  18 in total

1.  Long-Term stability of 6-hydroxymelatonin sulfate in 24-h urine samples stored at -20 degrees C.

Authors:  B Griefahn; T Remer; M Blaszkewicz; P Bröde
Journal:  Endocrine       Date:  2001-07       Impact factor: 3.633

Review 2.  The aging clock: circadian rhythms and later life.

Authors:  Suzanne Hood; Shimon Amir
Journal:  J Clin Invest       Date:  2017-02-01       Impact factor: 14.808

3.  Exogenous Melatonin for Delirium Prevention: a Meta-analysis of Randomized Controlled Trials.

Authors:  Sheng Chen; LiGen Shi; Feng Liang; Liang Xu; Doycheva Desislava; Qun Wu; Jianmin Zhang
Journal:  Mol Neurobiol       Date:  2015-07-21       Impact factor: 5.590

Review 4.  Circadian rhythm sleep disorders: pathophysiology and potential approaches to management.

Authors:  N Zisapel
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

5.  Circadian melatonin profiles during single 24-h shifts in anesthetists.

Authors:  Veronika Leichtfried; Gabriel Putzer; Dieter Perkhofer; Wolfgang Schobersberger; Arnulf Benzer
Journal:  Sleep Breath       Date:  2010-06-19       Impact factor: 2.816

Review 6.  Non-pharmacologic management of sleep disturbance in Alzheimer's disease.

Authors:  R David; J Zeitzer; L Friedman; A Noda; R O'Hara; P Robert; J A Yesavage
Journal:  J Nutr Health Aging       Date:  2010-03       Impact factor: 4.075

Review 7.  Melatonin and Multiple Sclerosis: From Plausible Neuropharmacological Mechanisms of Action to Experimental and Clinical Evidence.

Authors:  Mahshid Yeganeh Salehpour; Adriano Mollica; Saeideh Momtaz; Nima Sanadgol; Mohammad Hosein Farzaei
Journal:  Clin Drug Investig       Date:  2019-07       Impact factor: 2.859

8.  Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety.

Authors:  Alan G Wade; Ian Ford; Gordon Crawford; Alex McConnachie; Tali Nir; Moshe Laudon; Nava Zisapel
Journal:  BMC Med       Date:  2010-08-16       Impact factor: 8.775

9.  Urinary 6-sulfatoxymelatonin level in age-related macular degeneration patients.

Authors:  Richard Rosen; Dan-Ning Hu; Violete Perez; Katy Tai; Guo-Pei Yu; Min Chen; Paul Tone; Steven A McCormick; Joseph Walsh
Journal:  Mol Vis       Date:  2009-08-21       Impact factor: 2.367

10.  Chronotype differences in circadian rhythms of temperature, melatonin, and sleepiness as measured in a modified constant routine protocol.

Authors:  Leon Lack; Michelle Bailey; Nicole Lovato; Helen Wright
Journal:  Nat Sci Sleep       Date:  2009-11-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.